Margarita Sanchez Del Rio
Overview
Explore the profile of Margarita Sanchez Del Rio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
440
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Azorin D, Moya-Alarcon C, Armada B, Sanchez Del Rio M
J Headache Pain
. 2024 Mar;
25(1):38.
PMID: 38486155
Background: The burden of migraine goes beyond the pain and associated symptoms. We aimed to describe the impact of migraine in healthcare resource utilization (HCRU), work productivity, and mood disorders,...
2.
Sanchez Del Rio M, Cutrer F
Handb Clin Neurol
. 2023 Dec;
198:71-83.
PMID: 38043972
Migraine aura occurs in about a third of patients with migraine and consists of a group of transient focal neurological symptoms that appear from 5 to 60min and then resolve...
3.
Gallardo V, Alpuente A, Cerda-Company X, Torres-Ferrus M, Sanchez Del Rio M, Lainez J, et al.
Headache
. 2021 Oct;
61(9):1403-1410.
PMID: 34601726
Objective: This internet survey aimed to analyze the activity of midolordecabeza.org, a specialized website for headache stakeholders. Background: eHealth tools, such as websites, can be educational for stakeholders of a...
4.
Belvis R, Irimia P, Pozo-Rosich P, Gonzalez-Oria C, Cano A, Viguera J, et al.
J Headache Pain
. 2021 Jul;
22(1):74.
PMID: 34273947
Background: Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free...
5.
Citrome L, Sanchez Del Rio M, Dong Y, Nichols R, Tockhorn-Heidenreich A, Foster S, et al.
Adv Ther
. 2021 Jul;
38(8):4442-4460.
PMID: 34264500
Introduction: Subcutaneous galcanezumab was an effective, well-tolerated preventive treatment for adults with episodic (EM) or chronic migraine (CM) in 4 phase 3 randomized controlled trials: EVOLVE-1, EVOLVE-2, REGAIN, and CONQUER....
6.
Eigenbrodt A, Ashina H, Khan S, Diener H, Mitsikostas D, Sinclair A, et al.
Nat Rev Neurol
. 2021 Jun;
17(8):501-514.
PMID: 34145431
Migraine is a disabling primary headache disorder that directly affects more than one billion people worldwide. Despite its widespread prevalence, migraine remains under-diagnosed and under-treated. To support clinical decision-making, we...
7.
Sacco S, Lampl C, Brink A, Caponnetto V, Braschinsky M, Ducros A, et al.
J Headache Pain
. 2021 May;
22(1):39.
PMID: 34006218
Background: New treatments are currently offering new opportunities and challenges in clinical management and research in the migraine field. There is the need of homogenous criteria to identify candidates for...
8.
Mecklenburg J, Raffaelli B, Neeb L, Sanchez Del Rio M, Reuter U
Ther Adv Neurol Disord
. 2021 Jan;
13:1756286420967847.
PMID: 33403005
Lasmiditan, a highly selective 5-hydroxytryptamine receptor 1F (5-HT) agonist, is the first drug in its class and is lacking triptan-like vasoactive properties. The US Food and Drug Administration (FDA) has...
9.
Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, Brink A, et al.
J Headache Pain
. 2020 Jun;
21(1):76.
PMID: 32546227
Introduction: Despite advances in the management of headache disorders, some patients with migraine do not experience adequate pain relief with acute and preventive treatments. It is the aim of the...
10.
Mecklenburg J, Sanchez Del Rio M, Reuter U
Expert Rev Clin Pharmacol
. 2020 Jun;
13(6):641-654.
PMID: 32511056
Introduction: Cluster headache (CH) is the most common trigeminal autonomic cephalalgia with a significant need for novel treatment options. While the use of most of the acute CH medications is...